Curated News
By: NewsRamp Editorial Staff
June 24, 2025
Leksum's EVs Show Promise in Reducing MV-Related Lung Injury Risks
TLDR
- Leksum LLC's breakthrough with extracellular vesicles offers a competitive edge in ICU care by significantly reducing lung injury risks and improving patient recovery rates.
- Leksum's study methodically demonstrates that two doses of extracellular vesicles preserve diaphragm muscle fiber size and function by 93% and 94% respectively, compared to controls.
- This innovation by Leksum LLC promises to enhance millions of ICU patients' quality of life by mitigating ventilator-induced diaphragm dysfunction and reducing healthcare costs.
- Discover how Leksum LLC's extracellular vesicles could revolutionize ICU care by preserving diaphragm function and reducing lung injury in mechanically ventilated patients.
Impact - Why it Matters
This news is pivotal as it introduces a potential breakthrough in treating ventilator-induced diaphragm dysfunction, a common and costly complication for ICU patients. By preserving muscle function and reducing weaning times, Leksum's research could significantly lower mortality rates, improve quality of life for millions, and alleviate the financial strain on healthcare systems worldwide.
Summary
In a groundbreaking study by Leksum LLC, extracellular vesicles (EVs) have shown promising results in mitigating lung injury risks for ICU patients on mechanical ventilation (MV). Conducted at Leksum's state-of-the-art laboratory in Uppsala, Sweden, the study highlights significant improvements in diaphragm muscle fiber size and function after administering EVs, with even better outcomes observed from multiple doses. Professor Lars Larsson, Leksum’s Chief Scientific Officer, emphasizes the potential of EVs derived from bone marrow mesenchymal stromal cells (BM-MSCs) to preserve muscle function in immobilized MV patients. The findings, including preserved fiber cross-sectional area and specific force measurements, suggest a revolutionary approach to combating Ventilator Induced Diaphragm Dysfunction (VIDD), with Phase I trials in Europe on the horizon.
Leksum LLC, a Boston-based life sciences company, is pioneering advanced biologic therapies for muscle myopathies, including those resulting from MV use in ICUs. Their research not only aims to improve patient outcomes but also to reduce the global healthcare burden, estimated at over $100 billion annually for the weaning process alone. With additional studies on sarcopenia, cancer cachexia, and muscle-loss due to weight-loss drugs, Leksum is at the forefront of addressing critical muscle-related conditions.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Leksum's EVs Show Promise in Reducing MV-Related Lung Injury Risks
